



<b>Agenda Item No:</b>	<b>12</b>
------------------------	-----------

<b>Report to:</b>	Humber & North Yorkshire Integrated Care Board
<b>Date of Meeting:</b>	11 September 2024
<b>Subject:</b>	<b>Board Committees Assurance and Escalation Reports</b>
<b>Director Sponsor:</b>	Karina Ellis, Executive Director of Corporate Affairs
<b>Author:</b>	Mike Napier, Director of Governance & Board Secretary Sasha Sencier, Head of Governance and Development
<b>STATUS OF THE REPORT:</b>	
Approve <input type="checkbox"/> Discuss <input type="checkbox"/> Assurance <input checked="" type="checkbox"/> Information <input checked="" type="checkbox"/> A Regulatory Requirement <input type="checkbox"/>	

**SUMMARY OF REPORT:**

In accordance with the revised reporting arrangements previously agreed by the Board, this report sets out the consolidated summaries for each committee of the Board that has met in the time since the previous Board meeting. A rolling programme of reports will be submitted to the Board in accordance with the committee calendar and as soon as practicable following each committee meeting.

The summaries are provided to a consistent format and report by exception on:

- Matters and/or risks to bring to the attention of the Board, and
- Matters the committee was able to take positive assurance on or where additional information was required.

For August 2024, the following committee reports are attached within the supplementary information. Matters for the attention of the Board are summarised below.

Ref	Committee	Meeting Date	Matters for the attention of the Board
<b>A</b>	Workforce Board (Workforce Committee)	19 August	<ul style="list-style-type: none"> <li>• There are no alerts to escalate to the Board.</li> <li>• There is one matter to advise/assure the Board on.</li> </ul>
<b>B</b>	Pharmaceutical Services Regulations Committee (Committees in Common)	20 August	<ul style="list-style-type: none"> <li>• There are no alerts to escalate to the Board.</li> <li>• There are three other matters to advise /assure the Board on.</li> </ul>
		28 August	<ul style="list-style-type: none"> <li>• There are no alerts to escalate to the Board.</li> <li>• There are four other matters to advise /assure the Board on.</li> </ul>
<b>D</b>	IRIS	20 August	<ul style="list-style-type: none"> <li>• There is one alerts to escalate to the Board regarding a proposal to merge the IRIS Committee with the Digital Strategy Committee to enhance governance and efficiency. Both Committees seek the ICB Board's approval to form the new Digital, Data, Innovation, Research, and Continuous Improvement Committee (name TBC). If</li> </ul>

			<p>approved, draft the Terms of Reference will be developed for approval at the October Board.</p> <ul style="list-style-type: none"> <li>• There are no other matters to advise/assure the Board on.</li> </ul>
--	--	--	--

Finally, the feedback summary to committees from the June Board meeting are detailed at the end of this cover report.

**RECOMMENDATIONS:**

Members are asked to:

- Note the content of the Committee Assurance and Escalation Reports.

**ICB STRATEGIC OBJECTIVE**

Leading for Excellence	☒
Leading for Prevention	☒
Leading for Sustainability	☒
Voice at the Heart	☒

**IMPLICATIONS**

Finance	<b>The Finance, Performance and Delivery Committee</b> is responsible for overseeing, monitoring, and reviewing the stewardship of the finances, investments and sustainability of the ICB, including planning, financial performance, capital expenditure and the delivery of the informatics and estates, facilities and capital development annual plans
Quality	<b>The Quality Committee</b> provide the ICB with assurance that is delivering its functions in a way that secures continuous improvement in the quality of services, against each of the dimensions of quality set out in the Shared Commitment to Quality and enshrined in the Health and Care Act 2021. This includes reducing inequalities in the quality of care.
HR	<b>The Workforce Committee (aka Workforce Board)</b> provide strategic system oversight of the development and delivery of the Humber and North Yorkshire People Strategy and associated HNY people focused workstreams
Legal / Regulatory	The ICB Constitution and Standing Orders details that Committees of the Board are required to submit agreed key messages of each of its meetings, for information, to the Board.
Data Protection / IG	There are no direct data protection / IG implications relating to this paper. <b>The Audit Committee</b> receives regular updates on IG compliance (including uptake & completion of data security training), data breaches and any related issues and risks.
Health inequality / equality	<b>The Clinical and Professional Committee</b> provides population health led, strategic and collaborative clinical and professional oversight across the NHS Humber and North Yorkshire Integrated Care Board and support the Partnership to achieve its vision of helping the population to 'start well, live well, age well and end life well.'

	<b>The Population Health &amp; Prevention Committee</b> oversees the ICB's key ambition to improve outcomes in population health and healthcare.
Conflict of Interest Aspects	No conflicts of interest are identified in relation to this paper.  <b>The Audit Committee</b> oversees that the ICB's policy, systems and processes for the management of conflicts, (including gifts and hospitality and bribery) are effective including receiving reports relating to non-compliance with the ICB policy and procedures relating to conflicts of interest.
Sustainability	There are no sustainability implications relating to this paper.

**ASSESSED RISK:**

The ICB has a statutory and regulatory obligation to ensure that systems of control are in place, to minimise the impact of all types of risk.

**MONITORING AND ASSURANCE:**

The board remains accountable for all functions, including those that it has delegated to committees and, therefore, appropriate reporting and assurance arrangements are in place and documented in the terms of reference of each Committee.

**ENGAGEMENT:**

A wide variety of ICB subject matter specialists, senior officers and the ICB Board have been engaged in the development of this paper.

**REPORT EXEMPT FROM PUBLIC DISCLOSURE**

No  Yes

**August 2024  
Board Feedback Summary to Committees**

Committee	Meeting Date	Matters for the attention of the Board	Feedback to Committee
<b>Quality Committee / System Quality Group</b>	27 June	<ul style="list-style-type: none"> <li>• There is one alert to escalate to the Board regarding significant issues with ambulance handover delays.</li> <li>• There are ten other matters to advise/assure the Board on from the Quality Committee.</li> <li>• There are ten other matters to advise/assure the Board on from the System Quality Group.</li> </ul>	• No feedback required
<b>Workforce Board (Workforce Committee)</b>	15 July	<ul style="list-style-type: none"> <li>• There are no alerts to escalate to the Board.</li> <li>• There is one matter to advise/assure the Board on.</li> </ul>	• No feedback required
<b>Finance, performance &amp; Delivery Committee</b>	22 July	<ul style="list-style-type: none"> <li>• There is one alert to escalate to the Board:               <ul style="list-style-type: none"> <li>- The ICS faces a significant financial challenge with a high risk of overspending. To address this, the system is collaborating with NHS England to implement urgent measures, including external financial support. This support will focus on rapidly reducing expenditure, ensuring year-end breakeven, and delivering</li> </ul> </li> </ul>	• No feedback required

		<p>efficiency plans while safeguarding service quality and patient safety. The FPD has acknowledged the proactive actions being taken by system leaders to address this critical issue</p> <ul style="list-style-type: none"> <li>• There are ten other matters to advise/assure the Board on.</li> </ul>	
<b>Remuneration Committee</b>	24 July	<ul style="list-style-type: none"> <li>• There are no alerts to escalate to the Board.</li> <li>• There are three other matters to advise/assure the Board on.</li> </ul>	<ul style="list-style-type: none"> <li>• No feedback required</li> </ul>
<b>Pharmaceutical Services Regulations Committee (Committees in Common)</b>	31 July	<ul style="list-style-type: none"> <li>• There are no alerts to escalate to the Board.</li> <li>• There are seven other matters to advise /assure the Board on.</li> </ul>	<ul style="list-style-type: none"> <li>• No feedback required</li> </ul>
<b>Clinical &amp; Professional Committee</b>	2 August	<ul style="list-style-type: none"> <li>• There is one alert to escalate to the Board regarding high cost drugs, in particular NICE Technical Appraisals. Although the ICB is legally required to approve these drugs/devices and patients have a right to access them if appropriate, there are finite resources as a system.</li> <li>• There are four other matters to advise /assure the Board on.</li> </ul>	<ul style="list-style-type: none"> <li>• No feedback required</li> </ul>
<b>Population Health &amp; Prevention Committee</b>	9 May	<ul style="list-style-type: none"> <li>• There is one alert to escalate to the Board regarding a celebration event to showcase work that has been done through the Health Inequalities (HI) resource and partnership work of the committee.</li> <li>• There are five other matters to advise /assure the Board on.</li> </ul>	<ul style="list-style-type: none"> <li>• No feedback required</li> </ul>

**END.**